Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. What is atrial fibrillation? Available from: https://www.nhlbi.nih.gov/health/health-topics/topics/af
   Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Stettin GD. Treatment of nonvalvular atrial fibrillation. West J Med. 1995;162:331–339.
   PubMedGoogle Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375.
   PubMed Web of Science ®Google Scholar
• Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004;57:798–806.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104.
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e531S–e575S.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Fuster V, Ansell J, et al. American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692–1711.
   PubMed Web of Science ®Google Scholar
• Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114:1290–1298.
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126:1938–1945.
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144–1150.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med. 2014;371:1464–1465.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–164.
   PubMed Web of Science ®Google Scholar
• Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114:1277–1289.
   PubMed Web of Science ®Google Scholar
• Bancroft T, Lim J, Wang C, et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38:545-556 e1-e6.
   PubMed Web of Science ®Google Scholar
• Sussman M, Ghate S, Sutherland S, et al. Resource use among nonvalvular atrial fibrillation patients. Am J Pharm Benefits. 2016;8(5):84–92.
   Web of Science ®Google Scholar
• Limone B, Lim J, Shrady G, et al. Comparison of healthcare resource utilization, costs and medication persistence among patients with non-valvular atrial fibrillation (NVAF), newly treated with dabigatran or warfarin in a US Medicaid population. American College of Preventive Medicine. February 25-28, 2015; Atlanta, GA.
   Google Scholar
• Fu A, Jain R, Sander S, et al. Healthcare resource utilization and costs among patients with non-valvular atrial fibrillation using dabigatran or warfarin for stroke prevention. Circulation: Cardiovascular Quality and Outcomes. 2014;7:A242.
   Google Scholar
• Fu A, Jain R, Sander S, et al. Healthcare utilization and medication persistence of dabigatran and warfarin use for stroke-prevention among newly-diagnosed patients with non-valvular atrial fibrillation. American College of Preventive Medicine. February 19-22, 2014; New Orleans, LA.
   Google Scholar
• Michels S, Sheer R, Ghate S, et al. All-cause and driver-specific health care resource utilization in newly diagnosed non-valvular atrial fibrillation patients newly initiating dabigatran and warfarin. Journal of Managed Care Pharmacy. 2014;20(4-a):S33.
   Google Scholar
• Iorga S, Bancroft T, Lim J, et al. Comparing medication persistence, healthcare resource utilization and costs among newly diagnosed, newly treated patients using dabigatran vs warfarin. Pharmacotherapy. 2014;34(6):e76.
   Google Scholar
• Francis K, Yu C, Alvrtsyan H, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31:2189–2195.
   PubMed Web of Science ®Google Scholar
• Johnson BH, Smoyer-Tomic KE, Siu K, et al. Readmission among hospitalized patients with nonvalvular atrial fibrillation. Am J Health Syst Pharm. 2013;70:414–422.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870.
   PubMed Web of Science ®Google Scholar
• Fonseca E, Sander SD, Hess GP, et al. Hospital admissions, costs, and 30-day readmissions among newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran etexilate or warfarin. J Manag Care Spec Pharm. 2015;21:1039–1053.
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker D, Hess G. Dabigatran etexilate is associated with shorter hospital length of stay and lower hospital costs compared to warfarin in treatment-naïve, newly diagnosed non-valvular atrial fibrillation patients.Circulation: Cardiovascular and Quality and Outcomes. 2012;5:A282.
   Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4:e001798-e001798.
   PubMed Web of Science ®Google Scholar
• Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244–252.
   PubMed Web of Science ®Google Scholar
• Mearns ES, White CM, Kohn CG, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.
   PubMedGoogle Scholar
• Cotte FE, Benhaddi H, Duprat-Lomon I, et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther. 2014;36:1160–1168.
   PubMed Web of Science ®Google Scholar
• Ghate SR, Biskupiak J, Ye X, et al. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011;17:672–684.
   PubMed Web of Science ®Google Scholar
• Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract. 2012;2012:645469.
   PubMedGoogle Scholar
• Hohl RJ. Anticoagulants: major advances without clear consensus. Clin Pharmacol Ther. 2016;100:116–118.
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6:567–574.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United States. PLoS One. 2016;11:e0157769.
   PubMed Web of Science ®Google Scholar